Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant746 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,430 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003880 | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | terminated | Phase 2 / Phase 3 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 16, 2015 | clinicaltrials |
| NCT00442598 | Safety and Efficacy Study of Glufosfamide in Ovarian Cancer | terminated | Phase 2 | 17 | Eleison Pharmaceuticals LLC.INDUSTRY | 1 | Mar 10, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT01584297 | Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary(GreKo) | terminated | Phase 2 | 6 | Grupo Español de Tumores Huérfanos e InfrecuentesOTHER | 1 | Jan 21, 2015 | clinicaltrials |
| NCT00312650 | Doxil and Gemcitabine in Recurrent Ovarian Cancer | terminated | Phase 2 | 24 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01747239 | Cabazitaxel in Platinum Refractory Ovarian Cancer | terminated | Phase 2 | 4 | Vejle HospitalOTHER | 1 | Dec 4, 2014 | clinicaltrials |
| NCT01149434 | Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers | terminated | Phase 1 / Phase 2 | 19 | University of UtahOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00418093 | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | terminated | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2014 | clinicaltrials |
| NCT00919984 | Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer | terminated | Phase 2 | 22 | Korea Cancer Center HospitalOTHER | 1 | May 9, 2014 | clinicaltrials |
| NCT00053833 | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 2 | Nov 8, 2013 | clinicaltrials |
| NCT01821859 | Abraxane/Bevacizumab | terminated | Phase 2 | 5 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 26, 2013 | clinicaltrials |
| NCT00748527 | Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 2 | 134 | Cancer Research UKOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00084448 | Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Jul 9, 2013 | clinicaltrials |
| NCT00002478 | Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Jun 10, 2013 | clinicaltrials |
| NCT00583622 | Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients | terminated | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2013 | clinicaltrials |
| NCT01383408 | Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection | terminated | Phase 2 | 752 | Schillerhoehe HospitalOTHER | 1 | May 7, 2013 | clinicaltrials |
| NCT00003386 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00003624 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00004037 | Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00006812 | Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 2 | Apr 11, 2013 | clinicaltrials |
| NCT00023907 | Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00091195 | Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer | terminated | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT00523809 | Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2013 | clinicaltrials |
| NCT00042952 | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer | terminated | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00840450 | Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin | terminated | Phase 2 | 14 | NYU Langone HealthOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT00005612 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer(ETC) | terminated | Phase 1 / Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 26, 2012 | clinicaltrials |
| NCT00516841 | A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer | terminated | Phase 2 | 16 | Facet BiotechINDUSTRY | 2 | Aug 23, 2012 | clinicaltrials |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | terminated | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00445549 | Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 26, 2012 | clinicaltrials |
| NCT00006262 | Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer | terminated | Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 11, 2012 | clinicaltrials |
| NCT00653328 | Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma | terminated | Phase 2 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00505661 | Letrozole in Patients With Ovarian Tumors | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 18, 2012 | clinicaltrials |
| NCT00418574 | Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients(MIMOSA) | terminated | Phase 2 / Phase 3 | 888 | Menarini GroupINDUSTRY | 9 | Nov 24, 2011 | clinicaltrials |
| NCT00926107 | Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse | terminated | Phase 2 | 9 | Hellenic Cooperative Oncology GroupOTHER | 1 | Nov 10, 2011 | clinicaltrials |
| NCT00051584 | Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer | terminated | Phase 2 | 60 | Seagen Inc.INDUSTRY | 1 | Oct 24, 2011 | clinicaltrials |
| NCT00082212 | A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma | terminated | Phase 2 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 9, 2010 | clinicaltrials |
| NCT00277290 | Study of XL999 in Patients With Previously Treated Ovarian Cancer | terminated | Phase 2 | 24 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT00034138 | A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | terminated | Phase 1 / Phase 2 | 24 | Unither PharmaceuticalsINDUSTRY | 1 | Dec 18, 2007 | clinicaltrials |
| NCT00034372 | Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma | terminated | Phase 2 | 102 | Unither PharmaceuticalsINDUSTRY | 2 | Dec 18, 2007 | clinicaltrials |
| NCT00086632 | Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment | terminated | Phase 2 | 40 | Unither PharmaceuticalsINDUSTRY | 0 | Dec 18, 2007 | clinicaltrials |
| NCT00189579 | Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer | terminated | Phase 2 | 45 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2007 | clinicaltrials |
| NCT00055432 | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer | terminated | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Sep 15, 2006 | clinicaltrials |
| NCT00194935 | Weekly Topotecan Therapy in Patients With Ovarian Cancer | terminated | Phase 2 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 13, 2006 | clinicaltrials |
| NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Apr 12, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Apr 16, 2015source: clinicaltrials